GlassScriptPhysician profile
Mukesh Lathia
NPI 1700820693
$1,998.92
in general payments reported to CMS, 2019-2025
19 companies · $391 in 2025
The $391 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $438 · 2020: $210 · 2021: $73.43 · 2022: $221 · 2023: $233 · 2024: $433 · 2025: $391.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,057.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,057.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $689.32 | 2019-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Otsuka America Pharmaceutical, INC. | $247.55 | 2019-2025 | Rexulti, Abilify Asimtufii |
| Abbvie INC. | $152.76 | 2021-2025 | |
| Alkermes, INC. | $149.79 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $95.36 | 2019-2024 | Austedo Xr |
| Lundbeck LLC | $93.33 | 2019-2025 | Brintellix, Rexulti |
| Supernus Pharmaceuticals, INC. | $88.12 | 2021-2023 | Qelbree |
| Neurocrine Biosciences, INC. | $78.25 | 2019-2025 | |
| Sunovion Pharmaceuticals INC. | $47.57 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $47.42 | 2020-2025 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $46.84 | 2022-2025 | Caplyta |
| Validus Pharmaceuticals LLC | $45.99 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $45.74 | 2025 | Cobenfy |
| Corium, LLC | $44.03 | 2022-2025 | Azstarys |
| Axsome Therapeutics, INC. | $42.33 | 2023-2025 | Auvelity |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sage Therapeutics, LLC | $25.07 | 2025 | |
| Indivior INC. | $23.52 | 2023 | Perseris |
| Vanda Pharmaceuticals INC. | $20.14 | 2025 | Fanapt |
| Tris Pharma INC | $15.79 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mukesh Lathia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.